Nanobiotix S.A - Asset Resilience Ratio
Nanobiotix S.A (NANO) has an Asset Resilience Ratio of 53.40% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Nanobiotix S.A's Asset Resilience Ratio has changed over time. Check Nanobiotix S.A PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Nanobiotix S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Nanobiotix S.A stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €24.12 Million | 53.4% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €24.12 Million | 53.40% |
Asset Resilience Insights
- Very High Liquidity: Nanobiotix S.A maintains exceptional liquid asset reserves at 53.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Nanobiotix S.A Industry Peers by Asset Resilience Ratio
Compare Nanobiotix S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Nanobiotix S.A (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Nanobiotix S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 65.90% | €44.43 Million ≈ $51.94 Million |
€67.42 Million ≈ $78.82 Million |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€93.90 Million ≈ $109.78 Million |
-- |
| 2022-12-31 | 4.70% | €2.81 Million ≈ $3.29 Million |
€59.77 Million ≈ $69.88 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€133.93 Million ≈ $156.57 Million |
-- |
| 2019-12-31 | 17.83% | €10.00 Million ≈ $11.69 Million |
€56.07 Million ≈ $65.56 Million |
-7.07pp |
| 2018-12-31 | 24.90% | €11.50 Million ≈ $13.45 Million |
€46.20 Million ≈ $54.01 Million |
+5.91pp |
| 2017-12-31 | 18.99% | €10.91 Million ≈ $12.76 Million |
€57.47 Million ≈ $67.18 Million |
-50.27pp |
| 2016-12-31 | 69.26% | €21.06 Million ≈ $24.62 Million |
€30.40 Million ≈ $35.54 Million |
-- |
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more